Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs 744

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 744 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Pipeline programs

Page 4 of 16

  1. PTC923, PTC923

    PTC THERAPEUTICS, INC.

    Metabolic Disorders - Phenylketonuria

    phase 3 small molecule active

    1 trial

  2. Pioglitazone and Azilsartan

    Takeda

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  3. Pioglitazone and Glimepiride

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  4. Pioglitazone-Azilsartan

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

  5. Placebo

    Takeda

    Diabetes

    phase 3 small molecule terminated

    1 trial

  6. Placebo

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials

  7. Placebo

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  8. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  9. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  10. Placebo of BELAPECTIN, BELAPECTIN

    GALECTIN THERAPEUTICS INC

    Esophageal Varices in NASH Cirrhosis

    phase 3 small molecule active

    1 trial

  11. Placebo to match LY

    Eli Lilly Co.

    Overweight or Obesity, OSA (Obstructive Sleep Apnea)

    phase 3 small molecule active

    1 trial

  12. Prompt aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  13. Prompt aflibercept

    Regeneron UK Limited

    Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  14. REGN4461 - Mibavademab

    Lacuna Pharma Pty Ltd

    Monogenic obesity

    phase 3 small molecule active

    1 trial

  15. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    NASH

    phase 3 small molecule active

    1 trial

  16. Rimonabant

    Sanofi Pasteur

    Obesity

    phase 3 small molecule terminated

    1 trial

  17. S005201-175

    The George Institute

    Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin

    phase 3 small molecule active

    1 trial

  18. SYR-472

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  19. SYR-472

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    5 trials

  20. Saxagliptin

    AstraZeneca

    Diabetes

    phase 3 small molecule completed

    1 trial

  21. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity Associated With Defects in Leptin-melanocortin Pathway

    phase 3 small molecule active

    2 trials

  22. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 3 small molecule active

    1 trial

  23. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Leptin Receptor Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  24. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 3 small molecule active

    3 trials

  25. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Pro-opiomelanocortin (POMC) Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  26. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Nephropathies

    phase 3 small molecule active

    1 trial

  27. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus (T1DM)

    phase 3 small molecule completed

    1 trial

  28. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  29. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  30. Sotagliflozin (SAR439954)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    4 trials

  31. Sotagliflozin Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial

  32. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  33. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 3 small molecule active

    3 trials

  34. TAK-559

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  35. TAK-559 and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  36. TAK-559 and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  37. TAK-559 and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  38. TAK-875

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  39. TAK-875

    Takeda

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  40. TAK-875

    Takeda

    Diabetic Patients

    phase 3 small molecule completed

    1 trial

  41. TAK-875

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    4 trials

  42. TAK-875

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  43. Tang-min Lin pill

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  44. Teplizumab

    Sanofi Pasteur

    Type 1 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  45. Teplizumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Nutritional and metabolic diseases

    phase 3 small molecule active

    1 trial

  46. Tesaglitazar

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  47. Tesaglitazar 0.5 or 1 mg

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  48. Tirzepatide

    Eli Lilly and Company

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

744 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.